BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 13, 2006
View Archived Issues
NPS Falls On Preos Approvable Letter; Safety Concerns Cited
NPS Pharmaceuticals Inc. received an approvable letter for Preos, its parathyroid hormone to reduce fracture risk, but the company’s shares fell 37.5 percent amid safety concerns raised by the FDA. (BioWorld Today)
Read More
Insmed Offering Raises $37.2M To Fund iPLEX, Other Programs
Read More
A Kinder, Gentler Place For Biotech Hallmark: Start-ups
Read More
Corautus Brings In $26.5M To Fund VEGF-2 Program
Read More
Other News To Note
Read More